THERAPEUTIC EFFECT OF COMBINED ULINASTATIN AND GLUTAMINE FOR EARLY ENTERAL NUTRITION IN PATIENTS WITH SEVERE PANCREATITIS
XIU YANG, YANJUN WEI, HUA LI, KE XU, GUANGRONG YE, YAN ZHANG, TAO LU, JUAN YAN, JIABING PENG, GE ZHANG *
Department of Critical Care Medicine, The First People’s Hospital of Longquanyi District, Chengdu, 610100, China
Download Full Article PDF
This study investigated the therapeutic effect of combining ulinastatin and glutamine with early enteral nutrition in patients with severe pancreatitis. A retrospective analysis was conducted on 104 patients admitted between June 2020 and June 2022, divided equally into control and experimental groups. The control group received ulinastatin and early enteral nutrition, while the experimental group received an additional glutamine supplement over two weeks. Results showed that the experimental group had significantly better clinical outcomes, including faster symptom recovery and improved biochemical parameters. Inflammatory markers such as LPS, TNF-α and IFN-γ decreased, while IL-2 levels increased. Gut flora improved with a decrease in Escherichia coli and Staphylococcus, and an increase in Bifidobacterium. Additionally, markers of oxidative stress, gut permeability, and organ function improved more significantly in the experimental group. Immune function indicators, including CD3+, CD4+/CD8+, neutrophil count, and CRP, also showed favourable changes. APACHE II scores and the incidence of complications were significantly lower in the experimental group. These findings suggest that the combined therapy of ulinastatin and glutamine enhances clinical efficacy, modulates inflammation, supports intestinal and immune function, and may offer a valuable approach to treating severe pancreatitis.
